Targeting DNA damage response pathways in tumor drug resistance: Mechanisms, clinical implications, and future...

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Targeting DNA damage response (DDR) pathways is a key strategy against cancers with repair defects.
• Tumor resistance to DDR-targeted therapies, like PARP inhibitors, is a significant clinical challenge.
• Mechanisms of resistance include pathway restoration, protein mutations, and altered drug metabolism.

Purpose of the Study:

• To comprehensively review the molecular mechanisms of DDR resistance in tumors.
• To explore the clinical implications of DDR resistance mechanisms.
• To discuss emerging strategies for overcoming DDR resistance.

Main Methods:

• Literature review and analysis of existing research on DDR pathways and resistance.
• Synthesis of information on molecular mechanisms, clinical implications, and therapeutic strategies.
• Identification of future research directions and technological advancements.

Main Results:

• Detailed analysis of various resistance mechanisms, including HR restoration and compensatory pathways.
• Exploration of clinical relevance of these mechanisms in current treatment paradigms.
• Identification of novel therapeutic approaches, including combination therapies and biomarker-driven precision medicine.

Conclusions:

• Understanding DDR resistance mechanisms is crucial for improving cancer therapy efficacy.
• Novel DDR inhibitors, combination therapies, and precision medicine hold promise for overcoming resistance.
• Advanced technologies like CRISPR screening and AI are vital for future discoveries in DDR resistance.